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The knowledge of disease mechanisms and the identification
of markers of disease development and progression, and for
therapy evaluation, are rapidly expanding. Early diagnosis,
possible disease prevention and individual therapy stratifica-
tion are important goals in health care. Nuclear medicine and
radiology are potentially able to satisfy these increasing
demands for diagnosis, prevention, pathophysiological under-
standing and treatment possibilities. An increasing number of
biomarkers, drugs, antibodies and peptides, contrast agents and
MRI sequences have also been developed for these purposes.
Together with this continuing search for the “holy grail” radio-
pharmaceutical, the use of hybrid imaging is another important
development in the field. A recent development in hybrid
cameras is the introduction of combined PET and MRI.
Despite the intriguing novelty, it is important to evaluate
carefully, in a cost–benefit manner, the possible advantages
and clinical applications of such an expensive tool.
Advantages in general of hybrid PET/MRI systems
While PET enables the acquisition of functional data at the
molecular level, MRI provides superior soft-tissue resolution
and anatomy along with semiquantitative macromolecular
information. Hybrid PET/MRI systems can combine these
imaging characteristics. PET/MRI systems can be either si-
multaneous or sequential. Although imaging data from sepa-
rate PET and MRI systems may be combined, simultaneous
imaging systems have major theoretical advantages that could
be of interest to the whole medical community. The general
advantages of a simultaneous PET/MRI system as compared
to conventional PET/CT systems are:
& Recording of dynamic and moving phenomena, which
could enable tracers with short half-lives to be studied
& Identical position of the patient during image acquisition
with both modalities leading to a substantial reduction in
motion artefacts due to heart beating, intestinal motion
and breathing.
& Absolute match between the tissue information of both
modalities under the same physiological conditions.
& Contrast-enhanced MRI information (e.g. on perfusion
and blood flow) can be used in the pharmacokinetic
modelling of the PET data, resulting in an improvement
in PET reconstruction and data analysis.
& Better localization of the PETsignal within the soft tissues.
& No radiation burden from the MRI part.
& Better application of the one-stop-shop principle for
simultaneous diagnostic-quality acquisition of nuclear
medicine and radiological images.
& More structural, functional and molecular imaging at the
same time.
On the other hand, compared to PET/CT, PET/MRI exami-
nations may result in a lower compliance by the patient,
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because of long examination times and noise. Furthermore,
MRI cannot image all body parts at once (different body parts
may require different MR acquisition sequences and probes).
This new hybrid technique may therefore require collabora-
tion between radiologists and nuclear medicine physicians for
image interpretation and might be more expensive than PET/
CT scans (both capital and running costs). It is therefore of
economical and clinical importance to correctly identify the
possible fields of relevance of PET/MRI over other imaging
techniques, especially PET/CT.
Our aim here was not to provide a cost–benefit analysis of
PET/MRI, but to highlight some possible fields of application
in which PET/MRI could be of great clinical relevance.
PET/MRI in infectious and inflammatory diseases
Until recently, functional imaging of inflammation and infec-
tion was mainly restricted to planar imaging and SPECT.More
and more PET radiopharmaceuticals have now become avail-
able allowing more sensitive detection and quantification of
specific aspects of inflammatory processes. There is substantial
potential in the application of hybrid whole-body PET/MRI to
the investigation of infectious and inflammatory diseases.
PETcan give functional information about the target organ,
including disease activity, release of cytokines and infiltration
of specific immune cell populations. However, PET does not
provide anatomical information, which can seriously hamper
accurate diagnosis. The use of hybrid PET/CT is of limited
added value in most cases of inflammation, since it lacks good
soft-tissue contrast. MRI offers better anatomical and tissue
contrast information, and macromolecular functional informa-
tion. Simultaneous acquisition of PET and MRI could over-
come these shortcomings by providing quantitative molecular
functional information concerning the inflammatory lesion,
and accurate localization as well as anatomical changes with
motion correction. This could improve differential diagnosis
and guide antiinflammatory treatment strategies, resulting in
better medical care.
The combination of PET radiopharmaceuticals and PET/
MRI imaging could significantly improve the sensitivity and
specificity of the diagnosis and follow-up treatment of in-
fectious and inflammatory diseases. It would allow more
accurate assessment of the extent and exact localization of
inflammatory lesions than PET alone or PET/CT, especially
in soft tissues that are prone to movement artefacts, for
example in vascular and cardiac infections, inflammatory
bowel disease (IBD) and diabetes. MRI now offers more
than just anatomical information, with functional MRI
(fMRI), including diffusion-weighted imaging (DWI), mag-
netic resonance spectroscopy (MRS) and perfusion imaging.
There have also been improvements in MRI contrast agents
which can be used with radiolabelled probes that may lead
to even more insights into the dynamics and characteristics
of the inflammatory process. A third interesting feature of
PET/MRI is motion correction based on MRI, which would
allow more accurate quantification of PET data, leading to
better treatment monitoring and the possibility of earlier
response evaluation.
We now describe some relevant infectious and inflamma-
tory diseases in which we foresee a clinical impact of PET/
MRI.
Type 1 diabetes mellitus
Insulin-dependent diabetes mellitus (IDDM) results from the
cell-mediated autoimmune destruction of beta cells of the
pancreas. The autoimmune process, called insulitis, precedes
the clinical onset of type 1 diabetes. When clinical symptoms
are observed, the autoimmune process is markedly advanced:
60–80% of the pancreas has been destroyed at the time of
diagnosis [1]. Several attempts to image insulitis and the beta-
cell mass have been made with both CT and MRI [2]. The
MRI approaches to the study of IDDM have mainly been
developed on animal models; a few studies have used mag-
netic nanoparticles as a contrast agent for MRI [3]. Similarly,
several PET and SPECT tracers, such as 18F-FDG, labelled
leucocytes, antibodies and immunoglobulins have been used
to try to detect insulitis [4–9]. However, none of these tracers
and imaging modalities are able to target specifically the
inflammatory process involved in insulitis.
Interleukin-2 (IL-2) labelled with 99mTc or 123I is a SPECT
radiopharmaceutical specific for the IL-2 receptor that is over-
expressed in infiltrating lymphocytes during the prediabetic
phase. Both tracers have been studied in animal models of
insulitis and in patients with newly diagnosed type 1 diabetes
[9–12]. The results were promising, but the signal in the
pancreas was still too low to be able to obtain quantitative
data. Therefore, the new PET tracer N-(4-[18F]fluorobenzyl)
interleukin-2 (18F-IL-2) was developed, a tracer that is able to
target specifically CD25-positive cells. 18F-IL-2 is a promis-
ing tracer for insulitis imaging because it combines the spe-
cific targeting of activated T-lymphocytes and the high spatial
resolution provided by PET. This tracer has already been
tested in diabetic prone rats and mice with good results in
terms of localization and quantification of insulitis.
MRI is now the noninvasive imaging tool of choice with
high spatial resolution and the highest soft-tissue contrast;
however it does not give any functional information. In
contrast, PET can give information about the physiological
status of the particular target organ. A disadvantage of PET
is that peristaltic motion of the abdominal organs, including
the pancreas, can cause artefacts in the PET image. PET/
MRI may be able to solve this problem by using the MRI
data to correct the artefacts in the PET imaging. In the case of
insulitis, combined and simultaneous PET/MRI imaging could
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provide the exact anatomical localization and the inflammatory
status of the pancreas, and this techniquemay provide a unique
opportunity to quantify insulitis in humans. Thus, following
further development, this method could improve the diagnostic
accuracy of insulitis imaging and could be used in the routine
follow-up of diabetic patients.
To summarize, PET/MRI in IDDM may provide the
opportunity to:
& Visualize the cell-mediated autoimmune destruction of
beta cells of the pancreas (insulitis) at an early stage
& Quantify insulitis at an early stage
& Accurately diagnose insulitis and routinely follow-up
diabetic patients.
Spondylodiscitis
Spondylodiscitis is the main manifestation of haematoge-
nous osteomyelitis and represents 3–5% of all cases of
osteomyelitis [13]. The incidence has risen over the years
as a result of an increase in the susceptible population
(increase in average age, immunodeficiency, chronic steroid
use, infections associated with health care), an increase in
the number of patients undergoing spinal surgery, and better
diagnostic possibilities. Diagnosis is often delayed due to
the insidious nature of symptom onset and the high frequen-
cy of low back pain in the general population [14]. The
literature refers to an average diagnostic delay of 2–6 months
from the onset of clinical signs [13]. Diagnosis of spondy-
lodiscitis is based on clinical, laboratory and radiological
features and is often difficult to establish.
MRI is the modality of choice when clinicians have a
suspicion of a spinal infection. MRI has advantages over CT
because it can better distinguish bone marrow, vertebra and
intervertebral disc, is better able to evaluate the neural struc-
tures (including the spinal cord, epidural space and peripheral
soft tissue) and uses no radiation. Good sensitivity and speci-
ficity data have been reported for the use of MRI in spondylo-
discitis [15]. Therefore, MRI can currently be considered the
best conventional imaging method for diagnosis. However, the
results for the use ofMRI for treatment response monitoring in
patients with spinal infections are less clear.
In nuclear medicine, 18F-FDG is nowadays considered the
gold standard technique to detect spondylodiscitis and to
evaluate therapy success since radiolabelled white blood cells
do not migrate in the infected intervertebral discs and vertebral
bodies due to modification of the portal-like vascularization as
a result of oedema associated with the infection. The limita-
tion of FDG its the non-ability to differentiate between spon-
dylodiscitis and tumour (metastases) and the limited spatial
resolution (not possible to distinguish between vertebra, inter-
vertebral disc and bone marrow).
The combination and strengths of bothmodalities combined
in a simultaneous PET/MRI study could be of relevance in
patients with suspected spondylodiscitis. The main goals are:
& To assess if sensitivity and specificity of the diagnosis will
improve by combining PET and MRI simultaneously
& To assess if this hybrid imaging could be used for
follow-up during treatment
Inflammatory bowel diseases
IBD are represented mainly by two disorders: ulcerative
colitis and Crohn’s disease. A key role in the development
of these diseases is played by the infiltration and activation
of leucocytes, macrophages and T-cells [16]. These cells and
other molecular markers in the process such as chemokines,
cytokines and receptors of the immune response system can
be used as markers for scintigraphic imaging. At the mo-
ment, colonoscopy and/or small-bowel follow through are
considered by most to be the gold standard imaging techni-
ques for the diagnosis of IBD. However, since the majority
of patients need long-term follow-up it would be ideal to
rely on a noninvasive technique with good compliance.
With the possibility of intravascular specific contrast agents
for blood enhancement, CT, ultrasonography and MRI are all
able to detect increases in biological or endoscopic signs of
disease activity (vessel dilation, wall thickening, wall stratifi-
cation with thickening of the submucosa, wall and mesenteric
hypervascularity, lymph-node enlargement and enhance-
ment). In comparison with CT and ultrasonography, MRI
has shown a higher sensitivity in detecting these signs of
intestinal and mesenteric inflammation. MRI has an intrinsi-
cally higher soft-tissue contrast and sensitivity for inflamma-
tory abdominal tissues [17]; moreover, signs of inflammation
can be detected and analysed using different MRI parameters.
T1-weighted MRI parameters are similar to those in contrast-
enhanced CT or contrast-enhanced ultrasonography, whereas
other parameters are absolutely specific for MRI, such as
T2-weighted or diffusion imaging parameters. In general,
both T1- and T2-weighted MRI parameters have been
successfully and reliably correlated with signs of active
Crohn’s disease [18, 19]. The potential of the newest
developments in MRI techniques, such as MRS, DWI and
molecular imaging, is still unknown. MRS is used to
measure the levels of different metabolites in body tissues.
The characteristics of the resulting spectra can be used to
diagnose metabolic disorders [20].
DWI expresses molecular diffusion, which is the thermally
induced Brownian motion of water molecules, without the
administration of any contrast agent [18]. DWI is used in solid
organs such as the liver, pancreas, spleen and kidney. DWI has
not been commonly used for imaging of the intestinal tract
because image quality is severely degraded bymotion artefacts
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related to intestinal motion. However, recently free-breathing
DWI sequences which are associated with fewer motion arte-
facts have been introduced. This technique may allow the
evaluation of IBD. DWI has shown the ability to differentiate
active from inactive disease, as well to perform a quantitative
analysis of disease activity [21].
Huge advantages from the use of hybrid PET/MRI systems
in IBD may be expected. Cells can be labelled with radio-
nuclides, with fluorescent or bioluminescent markers (optical
imaging) or with MRI contrast agents, defined as molecular
MRI [22]. The combined use of nuclear medicine techniques
(PET for imaging cells and molecular events involved in the
disease) and MRI (for morphological definition of affected
bowel segments) is the key for the future approach to IBD.
We foresee further developments in molecular MRI combined
with nuclear medicine imaging, which could be effectively
used in the detection of active inflammatory cells and cytokines
in IBD.
The main goal for PET/MRI in IBD therefore should be
to assess if combined PET/MRI using targeted molecular
imaging and different MRI techniques (MRS, DWI) is able
to detect IBD with high accuracy.
Diabetic foot infection
Foot infections are one of the most common and severe com-
plications of diabetes mellitus. Detection, however, can be
difficult. On clinical examination it is difficult to differentiate
between soft-tissue infection and osteomyelitis. Infection
parameters in the blood (erythrocyte sedimentation rate,
C-reactive protein) are not specific. Bone biopsy is not always
performed because it is an invasive procedure that loses its
reliability if the biopsy fragments are contaminated by cutane-
ous bacteria. Therefore, imaging is crucial in diagnosing and
evaluating diabetic foot infections. Plain radiography and CT
are routinely used, but are not accurate enough. MRI is able to
differentiate between osteomyelitis and soft-tissue infection,
but the specificity is reduced if bony destruction, dislocation,
marrow oedema, synovial effusion and loss of bone and joint
limits are present (which are characteristic of neuropathic
Charcot’s joints) as well as osteomyelitis.
Nuclear medicine techniques play an important role in
the diagnosis of diabetic foot infections. White blood cell
scintigraphy with either 99mTc-exametazime (HMPAO) or
111In-oxine is currently the gold standard radionuclide tech-
nique for the diagnosis of osteomyelitis [23]. The labelling
method is well described in several guidelines [24, 25].
Another possibility is the use of 18F-FDG, but routine
FDG PET protocols cannot reliably distinguish infection
from inflammation. No acquisition protocols for FDG PET
in the diabetic foot have yet been validated and only a few
studies comparing FDG PET and white blood cell scintig-
raphy are available [26].
Combining MRI and nuclear medicine imaging may help
improve the accuracy in diagnosing diabetic foot infections.
The sensitivity of MRI alone or FDG PET alone is not high
enough, but as for PET/CT, we think combined imaging
improves sensitivity as well as specificity.
Therefore, in comparison with PET or MRI alone, hybrid
PET/MRI imaging could:
& Improve accuracy in the diagnosis of diabetic foot
infection
& Improve differentiation of osteomyelitis, Charcot’s joint
and soft-tissue infections
Other possibilities for the use of MRI in infectious
and inflammatory diseases
Over the past decade, MRI has gained importance in the
evaluation of infectious and inflammatory diseases. On
T2-weighted images, infiltrated tissues exhibit a hyperintense
signal which resolves after successful treatment. Thus, MRI
allows follow-up of lesion development in time and space.
However, as an important constraint, MRI only reflects non-
specific proton changes caused by a variety of different pro-
cesses rather than just tissue infiltration by mononuclear cells.
It does not visualize histological details such as the accumu-
lation of inflammatory cells in nuclear medicine. Therefore,
there is a demand for further developments in the field of
molecular MRI with the use of new contrast agents and fMRI
sequences.
Conclusion
The ability to image inflammatory processes at the molecular
and cellular levels would dramatically improve diagnostic
capabilities as well as provide in-depth data for new drug
development and biological understanding of the inflamma-
tory processes under different conditions. MRI contrast agents
to enhance the detection of inflammation and fMRI are under
development. For PET, several radiopharmaceuticals are
already in clinical use with high sensitivity and specificity but
with relatively low spatial resolution, although some studies
have found the technique sufficient for inflammation locali-
zation. However, this approach has not been widely embraced
for monitoring therapeutic responses.
We have only mentioned some inflammatory indications in
which hybrid PET/MRI imaging could help solve diagnostic
and evaluation problems. There are of course many more
diseases in which PET/MRI could be helpful, e.g. autoim-
mune pancreatitis, rheumatoid arthritis, transplant rejection,
vasculitides, inflammatory brain disorders, and pericarditis.
748 Eur J Nucl Med Mol Imaging (2012) 39:745–749
This editorial emphasizes the emerging importance of
PET/MRI in the field of inflammation and infection im-
aging, but we also emphasize the intrinsic difficulties in
the use this approach in humans. The future is to combine
PET imaging with MRI not only to increase anatomical
resolution but also for cell and molecular imaging, and to
bring the technology to the highest possible stage of
development so that the potential of these two unique
modalities in combination can be realized.
We leave others to calculate the cost–benefit ratio of PET/
MRI in these diseases, but from the medical and scientific
point of view the challenge is high.
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